TransCode Therapeutics, Inc. Share Price

TransCode Therapeutics, Inc. Share Price

NASDAQ: RNAZ
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

TransCode Therapeutics, Inc. Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

TransCode Therapeutics, Inc. Share Price Chart

Line chart of the TransCode Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 1.75 to 1.78, ending at 1.75.
$0.00$0.00
L
Show Current Price
H

TransCode Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.73
Revenue (TTM)
$0.00
Return On Equity (TTM)
167.12%
Profit Margin
N/A
Debt to Equity
-0.02
Quarterly Earnings Growth YoY
-41.36%

TransCode Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$4.86-$15.05-$19.51-$6.87
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-209.67%-29.63%64.79%

TransCode Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$17.56-$18.55-$16.79-$36.27
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-5.64%9.49%-116.02%

About TransCode Therapeutics, Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

TransCode Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

RNAZ Share Price FAQs